FindTrial
Sign In

Vimseltinib

DRUG7 trials

Sponsors

Deciphera Pharmaceuticals, LLC

Conditions

Advanced Malignant NeoplasmChronic Graft-Versus-Host Disease (cGVHD)Giant Cell Tumor of Tendon SheathHealthy Male ParticipantsHealthy ParticipantsPigmented Villonodular SynovitisTenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, Diffuse

Phase 1

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Active, not recruitingNCT03069469
Deciphera Pharmaceuticals, LLCAdvanced Malignant Neoplasm, Giant Cell Tumor of Tendon Sheath, Pigmented Villonodular Synovitis +2
Start: 2017-02-16End: 2028-08-01Target: 120Updated: 2026-06-25
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
CompletedNCT07158398
Deciphera Pharmaceuticals, LLCHealthy Participants
Start: 2025-10-31End: 2025-12-08Updated: 2026-01-15
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
CompletedNCT07158411
Deciphera Pharmaceuticals, LLCHealthy Participants
Start: 2025-11-20End: 2026-01-30Updated: 2026-02-11
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
RecruitingNCT07539090
Deciphera Pharmaceuticals, LLCHealthy Participants
Start: 2026-06-05End: 2026-10-01Target: 24Updated: 2026-09-03
Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
Not yet recruitingNCT07744802
Deciphera Pharmaceuticals, LLCHealthy Male Participants
Start: 2026-09-01End: 2026-12-01Target: 20Updated: 2026-09-02

Phase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingNCT06619561
Deciphera Pharmaceuticals, LLCChronic Graft-Versus-Host Disease (cGVHD)
Start: 2024-11-21End: 2029-10-31Target: 48Updated: 2025-12-15

Phase 3

Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Active, not recruitingNCT05059262
Deciphera Pharmaceuticals, LLCGiant Cell Tumor of Tendon Sheath, Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor +2
Start: 2021-10-14End: 2028-07-01Updated: 2026-03-20

Related Papers

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.
2026-09-01
Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
Journal of Clinical Oncology2025-05-28
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Clinical Cancer Research2024-07-1221 citations
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
2024-06-0333 citations
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
Journal of Clinical Oncology2024-06-012 citations
The MOTION Study: A Randomized, Phase III Study of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor
Future Oncology2023-08-1812 citations
MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.
Journal of Clinical Oncology2022-06-013 citations
Abstract C087: Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor
Molecular Cancer Therapeutics2019-12-018 citations